Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Electronic Coding Overestimates Prevalence Of Barrett's Esophagus
In a review of more than 2,000 patients coded for Barrett"s esophagus, electronic diagnosis overestimated the prevalence of the disease according to researchers in California. They found that only 61.9 percent of patients assigned a billing diagnosis code for Barrett"s esophagus actually had Barrett"s esophagus after a manual record review. The study evaluated the accuracy of diagnostic codes for Barrett"s esophagus by contrasting codes from electronic databases with diagnoses from a detailed medical record review. Researchers also evaluated the reproducibility of a pathologic diagnosis of Barrett"s esophagus between two pathologists and between a single pathologist on two different occasions. The study appears in the May issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).
generic viagra online
China Aoxing Pharmaceutical Company Announces Completion Of Registration Trial Of Its Leading Narcotic Drug For The Treatment Of Cough
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and marketing of narcotic and pain-management products, announced that it has completed the registration trial with Codeine Phosphate, a compound oral solution for the treatment of acute moderate to severe cough. Top-line results from this trial are expected to be announced by the end of the third quarter of 2009.
News of the day
Yale Researchers Find Key 'Conductor' Of Nature's Synchronicity
Synchronicity in nature is seen in beating hearts, the flashing of fireflies" lights, the ebb and flow of infectious disease-and the simultaneous rise and fall of populations across vast reaches of space. While scientists have identified some factors that account for this melodic phenomenon, they have yet to sort out the relative contribution each plays in this finely tuned orchestra.
Nutrition

Meda: FDA Approval For Onsolis Anticipated During Summer 2009

Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain). Last Friday, FDA"s review Division informed Meda and BDSI that they had reached agreement with the REMS for Onsolis, but that the FDA needed some additional time to complete the final senior level sign off. Meda therefore expects Onsolis to be approved by the FDA during summer, which could enable a fourth quarter 2009 launch, as previously anticipated. MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships drive the company"s strategy. Meda is represented by its own organizations in about 40 countries. Meda"s products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit http://www.meda.se. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009